Christopher Anzalone - Jan 7, 2022 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher Anzalone
Stock symbol
ARWR
Transactions as of
Jan 7, 2022
Transactions value $
$61,273
Form type
4
Date filed
1/7/2022, 08:39 PM
Previous filing
Jan 4, 2022
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Options Exercise $61.3K +11.8K +0.29% $5.19* 4.06M Jan 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARWR Stock Option (right to buy Common Stock) Options Exercise $0 -11.8K -1.53% $0.00 761K Jan 7, 2022 Common Stock 11.8K $5.19 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.
F2 Represents first vesting date. Option vested over four years from date of grant.
F3 Represents total stock options beneficially owned at various strike prices.